In a small, double-blind, placebo-controlled, randomized clinical trial (RCT) in 60 DM subjects with CAD, supplementation with melatonin (10 mg od) for 12 weeks increased plasma GSH, NO, and decreased MDA and C-reactive protein (CRP) vs. placebo [220] (Table 4). This evidence concerns the gene CRP and coronary artery disorder.